Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology Co., Ltd. has reported preliminary unaudited figures for 2025 prepared under China Accounting Standards, indicating a decline in both revenue and profitability. The company cautioned investors that these numbers are subject to change pending the audited annual results and advised attention to potential investment risks.
Total revenue for 2025 fell 8.33% year-on-year to RMB 24.73 billion, while operating profit dropped 55.43% and net profit attributable to shareholders declined 40.30%. Earnings per share slid 40% and return on net assets deteriorated, reflecting weaker core performance after non-recurring items as well as modest reductions in total assets and shareholders’ equity.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong and Shanghai that develops and manufactures biomedical products. The group focuses on ophthalmic, orthopaedic and other medical applications, serving hospital and clinical markets in its domestic market and potentially abroad.
Average Trading Volume: 166,916
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.13B
Find detailed analytics on 6826 stock on TipRanks’ Stock Analysis page.